DexComDXCMRevenue: is the business selling more than it used to?
$4.7B+16% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $4.7B in 2025, compounding +17% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $5.0B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMNet income: how much of that revenue becomes profit?
$836M+45% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $836M in 2025, compounding +35% a year over three years. Earnings per share moved +75% over the last twelve months. Trailing twelve-month profit stands at $1000M.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMHow fast is it growing, year by year?
+15.6%revenue growth, FY 2025
Off the axis: 2020 earnings +443.7% - rebounds off a collapsed prior year.
→Revenue grew +16% in 2025 against a five-year average of +19%. Earnings grew faster (+45%), so each new dollar of sales is arriving more profitably. 2020's +444% earnings rebound off a collapsed base sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMRevenue per share: is your slice growing as fast as the company?
$11.50revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $11.50 in 2025, compounding +19% a year against +17% for DXCM as a whole. Buybacks added roughly 2.1 points to your per-share result. Free cash flow per share stands at $2.66.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMFree cash flow: what is left in real cash after everything?
$1.1B+71% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $1.1B in 2025, compounding +52% a year since 2022. That is the most cash the business has ever thrown off in a year. The trailing twelve months stand at $1.4B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMWhere does each dollar of revenue actually go?
→Of $4.7B in 2025 sales, $836M reaches net profit - 18 cents on the dollar. The largest single deduction is running the company ($1.9B).
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→23 cents of every sales dollar became free cash in 2025, up 13 points since 2022 - the best conversion in its filed history.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 13% of revenue (capital spending 8%, stock compensation 3%). That share has fallen since 2022, so the cost of competing is easing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMWhen sales grow, do profits grow faster?
→Operating profit outgrew revenue in 3 of the last 5 years, most recently +52% against +16%. Each additional dollar of sales is landing more profitably than the last - the definition of operating leverage.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin widened 6 points to 20% since 2022. After everything, 18 cents of each sales dollar reaches net profit.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of 38% sits well above ROCE of 22%. A meaningful share of the shareholder return is manufactured with leverage rather than operations.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMWhat has the market paid for DXCM over time?
35.7xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 35.7x earnings, the market is paying 59% less than DXCM's own 7-year median of 87.9x. Pessimism is priced in - the question is whether it is deserved. Today's multiple is the lowest in the charted history.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMWhat cash return does the business throw off per dollar of market value?
4.2%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 4.2% of annual free cash flow, more than its 9-year median of 0.8% - the cash is cheaper than usual.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMCould it handle its debt if things went wrong?
→Debt isn't clearly tagged in DXCM's filings, so treat the balance sheet with extra care rather than assuming zero.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMIs the company's own capital growing?
→The company's own capital grew from $2.1B in 2023 to $2.6B (+27%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMHow much goes back, and how much leaks out as stock comp?
→Shareholders received $500M in buybacks in 2025. Stock compensation issued $160M of new shares in the same year, offsetting 32% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMHow fast is your ownership being diluted - or concentrated?
→The share count shrank 1.7% in 2025, averaging 1.7% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMDoes DXCM earn more on its capital than that capital costs?
→DXCM earns 21.7% on the capital it employs, well above the 10% most investors treat as the cost of capital. It was 11.0% in 2022, so the trend is up, and the pace is picking up. That is the highest in DXCM's filed history.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMDXCM has issued or retired shares - did shareholders end up better off?
→DXCM issued +17% more shares from 2017 to 2025, but revenue per share still rose +452%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
DexComDXCMAre the people running it buying or selling?
→Insiders sold $11M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 28 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30